Joe Bentz
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Michael P. O’Connor
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Dallas Bednarczyk
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
JoAnn Coleman
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Caroline Lee
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Johan Palm
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Y. Anne Pak
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Elke S. Perloff
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Eric Reyner
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Praveen Balimane
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Marie Brännström
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Xiaoyan Chu
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Christoph Funk
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Ailan Guo
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Imad Hanna
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Krisztina Herédi-Szabó
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Kate Hillgren
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Libin Li
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Evelyn Hollnack-Pusch
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Masoud Jamei
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Xuena Lin
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Andrew K. Mason
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Sibylle Neuhoff
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Aarti Patel
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Lalitha Podila
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Emile Plise
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Ganesh Rajaraman
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Laurent Salphati
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Eric Sands
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Mitchell E. Taub
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Jan-Shiang Taur
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Dietmar Weitz
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Heleen M. Wortelboer
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Cindy Q. Xia
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Guangqing Xiao
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Jocelyn Yabut
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Tetsuo Yamagata
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Lei Zhang
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)
Harma Ellens
Drexel University, Department of Biology, Philadelphia, PA (J.B., M.P.O’C.); Optivia, Biotechnology, Menlo Park, CA (D.B.); GlaxoSmithKline Pharmaceuticals, Statistical Sciences (J.C.); Drug Metabolism and Pharmacokinetics, King of Prussia, PA (H.E.) and Ware, UK (A.P.); Pfizer, Inc., Department of Pharmacokinetics, Dynamics and Metabolism, San Diego, CA (C.L., E.R.); AstraZeneca R&D Mölndal, Innovative Medicines, CVGI iMed DMPK, Mölndal, Sweden (J.P.); Eli Lilly and Company, Investigative Drug Disposition, Lilly Research Laboratories, Indianapolis, IN (Y.A.P., K.H.); BD Biosciences Discovery Labware, BD GentestSM Contract Research Services, Woburn, MA (E.S.P., A.K.M.); AstraZeneca R&D Mölndal, Innovative Medicines, R&I iMed DMPK (M.B.); Bristol-Myers Squibb, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ (P.B.); Merck & Co., Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Rahway, NJ (X.C., J.Y.); Non-Clinical Drug Safety, F. Hoffmann-La Roche, Basel, Switzerland (C.F., E.H.-P.); Non-Clinical Drug Safety, Hoffmann-La Roche, Nutley, NJ (A.G.); Novartis Institutes for BioMedical Research, East Hanover, NJ (I.H.); SOLVO Biotechnology, Budapest, Hungary (K.H.-S.); Absorption Systems LP, Exton, PA (L.L.); Simcyp (a Certara company), John Street, Sheffield, UK (M.J., S.N.); Novartis Institute for BioMedical Research, Cambridge, MA (X.L.); Boehringer Ingelheim Pharmaceuticals, Inc., Drug Metabolism and Pharmacokinetics, Ridgefield, CT (L.P., M.E.T.); Genentech Inc., Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA (E.P., L.S.); CellzDirect-Life Technologies Ltd., Austin, TX (G.R.); Biogen Idec, Drug Metabolism and Pharmacokinetics, Cambridge, MA (E.S., G.X.); Eisai Inc., Andover, MA (J.T.); Sanofi-Aventis, R&D DSAR / Drug Disposition FF, Frankfurt am Main, Germany (D.W.); TNO, Zeist, The Netherlands (H.M.W.); Millennium Pharmaceuticals, Inc., Cambridge, MA (C.Q.X.); Merck Serono, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany (T.Y.); Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (L.Z.)